Trials / Unknown
UnknownNCT04877496
Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.
Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 425 (estimated)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Patients with treatment history of rituximab since 01.01.2019 and immunocompetent volunteers will be contacted to give a blood sample after their COVID19 vaccination, and in a subset also before vaccination. Immune responses of antibodies and SARS-CoV2-specific T-cells to the vaccination will be quantified and the rituximab effect on COVID19 vaccine-induced immune responses is analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | History of exposure to anti-CD20 treatment since 01/01/2010 | Intravenous treatment history of anti-CD20 treatment since 01/01/2010 |
| BIOLOGICAL | Completion of COVID19 vaccine at least 4 weeks ago | Completion of COVID19 vaccination course at least 4 weeks ago. |
Timeline
- Start date
- 2021-04-26
- Primary completion
- 2021-08-30
- Completion
- 2021-10-31
- First posted
- 2021-05-07
- Last updated
- 2021-06-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04877496. Inclusion in this directory is not an endorsement.